Market Cap: $10.82M
VI
VistaGen Therapeutics, Inc.
VTGN
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $10.82M
VistaGen Therapeutics (Ticker: VTGN) announces significant findings from their recent post-hoc analysis, targeting the treatment of very severe social anxiety disorder. This analysis reveals a statist…
VistaGen Therapeutics Faces Class Action Lawsuits Over Alleged Misleading Statements VistaGen Therapeutics, Inc. finds itself at the center of multiple class action lawsuits as a consortium of law fir…
VistaGen Therapeutics Faces Legal Challenges Amid Clinical Trial Controversy VistaGen Therapeutics, Inc. is currently embroiled in legal proceedings following allegations of misleading statements rega…
Vistagen Therapeutics Faces Class Action Lawsuits Amid Allegations of Misleading Statements In a significant development for Vistagen Therapeutics, Inc. (NASDAQ: VTGN), multiple law firms announce cla…
Vistagen's Misleading Trial Claims Lead to Legal Troubles Vistagen Therapeutics, Inc. faces significant legal challenges as multiple law firms announce class action lawsuits on behalf of investors. Th…
VistaGen Therapeutics Faces Class Action Lawsuits Over Alleged Misleading Statements VistaGen Therapeutics, a clinical-stage biopharmaceutical company, finds itself in the midst of multiple class acti…
### Vistagen Therapeutics Faces Legal Scrutiny Amid Class Action Lawsuits Vistagen Therapeutics, Inc. is currently navigating legal tumult, having been targeted by two separate class action lawsuits r…
VistaGen Therapeutics Faces Class Action Allegations Amid Clinical Trial Setbacks In a significant legal development, under scrutiny for potential securities fraud, VistaGen Therapeutics, Inc. (NASDAQ…
VistaGen on Trial: Allegations of Misleading Investors Following PALISADE-3 Results In recent developments, VistaGen Therapeutics, Inc. faces multiple class action lawsuits stemming from allegations o…
VistaGen Therapeutics Faces Class Action Lawsuits Over Alleged Misrepresentation of Clinical Trial Results VistaGen Therapeutics, Inc. is currently embroiled in legal challenges following the announce…
VistaGen Faces Class Action Lawsuits Over Alleged Misleading Statements VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for anxiety and depress…
Rosen Law Firm Files Class Action Lawsuit Against VistaGen Therapeutics Over Drug Development Miscommunication Rosen Law Firm has initiated a class action lawsuit against VistaGen Therapeutics, Inc. c…
Vistagen Therapeutics Faces Legal Scrutiny Following Phase 3 Trial Results Vistagen Therapeutics, Inc. is currently embroiled in a class-action lawsuit initiated by Levi & Korsinsky, LLP, following di…
VistaGen's Troubled Trail: Legal Scrutiny Follows Clinical Trial Setback VistaGen Therapeutics, Inc. faces significant scrutiny following the disappointing results of its Phase 3 PALISADE-3 clinical t…
VistaGen's Fasedienol Trial: Disappointing Results Prompt Allegations of Executive Misconduct In recent developments, VistaGen Therapeutics, Inc. faces significant scrutiny following the failure of it…
Vistagen Faces Class Action Over Fasedienol Communications Court Motion Looms Over Vistagen’s Fasedienol Program Rosen Law Firm is pressing potential lead plaintiffs in a class action tied to Vistagen…
Fasedienol Trial Dispute Drives Litigation Against VistaGen Therapeutics A pair of securities firms files class actions accusing VistaGen Therapeutics of misleading investors about the results and pro…
Two Firms File Class Actions Against VistaGen VistaGen Therapeutics faces parallel securities class actions filed by The Schall Law Firm and DJS Law Group alleging the company made false and misleadin…
Legal Scrutiny Centers on Vistagen’s Fasedienol Trial Claims Multiple U.S. law firms are pressing securities claims against VistaGen Therapeutics, focusing on the company’s public statements about fas…
Allegations of Misleading Clinical Claims Cloud Vistagen’s Fasedienol Program Vistagen Therapeutics faces multiple securities class action claims alleging the company misled investors about the prospe…
Legal Challenge Centers on Phase 3 Messaging VistaGen Therapeutics faces parallel securities class actions alleging the company mischaracterises the prospects of its fasedienol PALISADE‑2 Phase 3 tria…
VistaGen Faces Multiple Securities Claims Over Trial Communications Allegations Focus on PALISADE‑3 Disclosure Practices Several law firms are bringing securities class actions against VistaGen Therap…
Vistagen draws multiple securities suits after Phase 3 disclosure Allegations of Misleading Clinical Communications on Fasedienol Vistagen Therapeutics is facing coordinated securities class actions a…
VistaGen Therapeutics Faces Class Action Lawsuits Following Trial Disappointment VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is currently embroiled in multiple class action lawsuits stemming from alleg…
VistaGen Therapeutics Faces Class Action Lawsuit Over Alleged Misleading Statements In a significant legal development, VistaGen Therapeutics, Inc. finds itself at the center of a class action lawsuit…